{"id":749091,"date":"2023-04-19T09:14:28","date_gmt":"2023-04-19T13:14:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/"},"modified":"2023-04-19T09:14:28","modified_gmt":"2023-04-19T13:14:28","slug":"lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/","title":{"rendered":"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023"},"content":{"rendered":"
\n

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc.<\/a> (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.<\/p>\n

Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link<\/a>, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast may be accessed through this\u00a0Webcast Link<\/a> and may also be found in the \u201cInvestors & Media\u201d section of the Lumos Pharma website, under \u201cEvents & Presentations<\/a>.\u201d A replay of the call will be available after the date of the call and may be accessed through the same link above or found on our website.<\/p>\n

\n About Lumos Pharma<\/strong>\n <\/p>\n

Lumos Pharma, Inc.\u00a0is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.\u00a0Lumos Pharma\u00a0was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma\u2019s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK\/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https:\/\/lumos-pharma.com\/<\/a>.<\/p>\n

Investor & Media Contact:<\/p>\n

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com<\/a><\/p>\n

Source: Lumos Pharma, Inc.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with … <\/p>\n

Continue reading “Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749091","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with … Continue reading "Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-19T13:14:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023\",\"datePublished\":\"2023-04-19T13:14:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/\"},\"wordCount\":367,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/\",\"name\":\"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=\",\"datePublished\":\"2023-04-19T13:14:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/","og_locale":"en_US","og_type":"article","og_title":"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 - Market Newsdesk","og_description":"AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with … Continue reading \"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-19T13:14:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023","datePublished":"2023-04-19T13:14:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/"},"wordCount":367,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/","name":"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=","datePublished":"2023-04-19T13:14:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDQ2NiM1NTMzNDE4IzIwMTY1Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-3-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749091"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749091\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}